Skip to main content

Table 2 CRT changes following AFL PRN treatment

From: Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

CRT reduced

N (%)

CRT increased

N (%)

≥50μm

23 (12%)

≥50μm

38 (21%)

≥100μm

8 (4%)

≥100μm

16 (9%)

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us